Sarepta TherapeuticsNASDAQ: SRPT

Sarepta's Elevidys received expanded FDA approval to treat both ambulatory and non-ambulatory DMD patients aged four and above. Although Elevidys missed its primary endpoint, it demonstrated success on secondary measures like motor function improvement and time-to-rise. SRPT expects substantial revenue growth, projecting net product revenues of $2.9-3.1 billion by 2025.

Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have few options.

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm  Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9.

Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however, as the stock extends a bounce off the $125 level.

Vertex's newest approval and late-stage pipeline should yield stronger financial results. Smaller biotech Sarepta Therapeutics continues to innovate in its core therapeutic area.

Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations.

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.